Class-Action Lawsuit Charges EpiPen Maker Mylan With Price-Gouging

A new class-action lawsuit seeks damages for severe allergy sufferers who have been subjected to outrageous price hikes for the EpiPen injector. The lawsuit filed by The Lanier Law Firm charges that pharmaceutical giant Mylan Inc. implemented a series of aggressive price hikes and unconscionable sales tactics after acquiring rights to sell the EpiPen in 2007. The price of the EpiPen has increased from $57 in 2007 to more than $600 today.

Mylan CEO Heather Bresch knows that good hardworking Americans will do anything to protect loved ones from a deadly allergic reaction that could happen at any time, said attorney Mark Lanier, founder of The Lanier Law Firm. This company’s attempt to saddle consumers, insurance companies, Medicare and Medicaid with the bill for its outrageously overpriced product is indefensible. Mylan closely protects its monopoly on the EpiPen, which delivers life-saving medicine to fend off allergic reactions and generated nearly 4 million prescriptions last year. According to the lawsuit, the company’s pricing scheme results in excessive out-of-pocket expenses for the uninsured and those with high-deductible health insurance. Mylan is currently under investigation by the House Committee on Oversight and Government Reform, the Securities and Exchange Commission and state regulatory authorities for its EpiPen pricing scheme.

For more information, contact Robert Tharp at or 800-559-4534.

Are you ready to get started?